Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain-Reference-Cited by-同舟云学术

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

Published:2018-01-05 Issue:1 Volume:13 Page:e0190487
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kerrigan Deanna^ORCID,Mantsios Andrea,Gorgolas Miguel,Montes Maria-Luisa,Pulido Federico,Brinson Cynthia,deVente Jerome,Richmond Gary J.,Beckham Sarah W.,Hammond Paige,Margolis David,Murray Miranda

Funder

ViiV Healthcare

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference42 articles.

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact Sheet 2016. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.

2. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Available from: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.

3. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report 2014. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.

4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection;FJ Palella Jr;New England Journal of Medicine,1998

5. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease;TS Li;The Lancet,1998

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?;AIDS;2024-02-01

2. “What Is the Benefit?”: Perceptions and Preferences for Long-Acting Injectable Antiretroviral Therapy Among People Living With HIV;AIDS Education and Prevention;2023-12

3. Barriers and Facilitators to Equitable Implementation of Long-Acting ART for Adolescents and Youth with HIV in Low- and Middle-Income Settings;2023-11-15

4. Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives;Implementation Science Communications;2023-10-19

5. The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch;Current HIV/AIDS Reports;2023-09-21